(Q28366214)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

title

A phase I and pharmacokinetic study of intraperitoneal topotecan (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

L S Hofstra

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

A M Bos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

A G van der Zee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J H Beijnen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

H Rosing

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

N H Mulder

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J G Aalders

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

P H Willemse

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

language of work or name

English

0 references

publication date

1 November 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

4 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

1627-1633

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

4 December 2019

copyright license

start time

27 November 2001

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Topotecan, an active new antineoplastic agent: review and current status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Intraperitoneal chemotherapy in ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Clinical pharmacokinetics of topotecan

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

2 June 2018

1 reference

https://api.crossref.org/works/10.1054%2FBJOC.2001.2161

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1054%2FBJOC.2001.2161

Phase I and pharmacokinetic study of intraperitoneal topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1054%2FBJOC.2001.2161

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1054%2FBJOC.2001.2161

Image analysis of the distribution of intraperitoneally administered fluids in patients with ovarian cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363984

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

27 November 2018

1 reference

12 December 2020

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

1 reference

12 December 2020

Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin

1 reference

12 December 2020

Reduced Albumin Binding Promotes the Stability and Activity of Topotecan in Human Blood

1 reference

12 December 2020

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

12 December 2020

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

12 December 2020

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

12 December 2020

Back to the future: multiagent chemotherapy in ovarian cancer revisited

1 reference

12 December 2020

Intraperitoneal therapy of ovarian cancer

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2001.2161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 December 2019

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11742479%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

PubMed publication ID

11742479

1 reference